Winway Health Desk
Emerging trends for pancreatitis in the scientific literature: a new report
Posted on October 19th, 2021 by Ann-Marie Roche in Pharma...
Oyster Point dry eye drug is approved, but omission in label...
A medicine that initially reached the market as a smoking cessation pill now has new life as a dry eye disease drug in a...
UnityPoint Health, b.well Connected Health partner to implement digital-first consumer strategy
UnityPoint Health is undergoing an extensive digital transformation, and it has engaged health technology company b.well Connected Health to facilitate its efforts.
The Des Moines,...
Engage at HLTH: As patient engagement solutions abound, here’s what investors...
As patient engagement solutions proliferate, potential partners are looking for ones that are driving patient outcomes. Investors advised startups to work with trusted clinicians...
Engage at HLTH: At the heart of patient-centered care is trust...
Providing patient-centered care generally means ensuring the patient is the focal point of all clinical and operational decisions. Patient centricity is a strategic goal...
Regeneron, Novo Nordisk, Lilly and AbbVie stake claims on September’s list...
Call it a tale of two therapeutic fields. Immunology treatments and diabetes drugs together dominated September's list of top spenders on TV ads, with...
Healthcare marketing firm Relevate Health unveils brand refresh to highlight digital...
With fewer sales reps in the field and limited opportunities to engage with doctors face-to-face amid the pandemic, more pharma companies are turning to...
Insiteflow raises $2.3M to solve workflow interoperability
Insiteflow co-founder and CEO Anthony Gerardi. Photo credit: Insiteflow
New interoperability rules carry the promise of finally freeing up all of that data that’s been...
Pandemic launch woes: Esperion cuts 40% of workforce, goes all in...
Just as Esperion’s cholesterol sister meds Nexletol and Nexlizet launched at the start of the pandemic, pharma marketing went virtual. As its cash dwindles,...
Biogen ALS drug fails main goal of key test, but company...
A Biogen drug that addresses a subset of amyotrophic lateral sclerosis patients who have a particular genetic mutation has fallen short of the main...
